Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMidaglia Fernandez, Luciana
dc.contributor.authorMulero Carrillo, Patricia
dc.contributor.authorMontalban, Xavier
dc.contributor.authorGraves, Jennifer
dc.contributor.authorHauser, Stephen L.
dc.contributor.authorJulian, Laura
dc.date.accessioned2020-03-13T12:29:12Z
dc.date.available2020-03-13T12:29:12Z
dc.date.issued2019-08-30
dc.identifier.citationMidaglia L, Mulero P, Montalban X, Graves J, Hauser SL, Julian L, et al. Adherence and satisfaction of smartphone- and smartwatch-based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study. J Med Internet Res. 2019 Aug 30;21(8):e14863.
dc.identifier.issn1438-8871
dc.identifier.urihttps://hdl.handle.net/11351/4730
dc.descriptionSmartphone; Multiple sclerosis; Patient adherence
dc.description.abstractBackground: Current clinical assessments of people with multiple sclerosis are episodic and may miss critical features of functional fluctuations between visits. Objective: The goal of the research was to assess the feasibility of remote active testing and passive monitoring using smartphones and smartwatch technology in people with multiple sclerosis with respect to adherence and satisfaction with the FLOODLIGHT test battery. Methods: People with multiple sclerosis (aged 20 to 57 years; Expanded Disability Status Scale 0-5.5; n=76) and healthy controls (n=25) performed the FLOODLIGHT test battery, comprising active tests (daily, weekly, every two weeks, or on demand) and passive monitoring (sensor-based gait and mobility) for 24 weeks using a smartphone and smartwatch. The primary analysis assessed adherence (proportion of weeks with at least 3 days of completed testing and 4 hours per day passive monitoring) and questionnaire-based satisfaction. In-clinic assessments (clinical and magnetic resonance imaging) were performed. Results: People with multiple sclerosis showed 70% (16.68/24 weeks) adherence to active tests and 79% (18.89/24 weeks) to passive monitoring; satisfaction score was on average 73.7 out of 100. Neither adherence nor satisfaction was associated with specific population characteristics. Test-battery assessments had an at least acceptable impact on daily activities in over 80% (61/72) of people with multiple sclerosis.
dc.language.isoeng
dc.publisherJMIR Publications
dc.relation.ispartofseriesJournal of Medical Internet Research;21(8)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple
dc.subjectPacients - Cooperació
dc.subjectTelèfons intel·ligents
dc.subject.meshMultiple Sclerosis
dc.subject.meshPatient Compliance
dc.subject.meshWearable Electronic Devices
dc.titleAdherence and satisfaction of smartphone- and smartwatch-based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2196/14863
dc.subject.decsesclerosis múltiple
dc.subject.decscumplimiento del paciente
dc.subject.decsdispositivos electrónicos ponibles
dc.relation.publishversionhttps://www.jmir.org/2019/8/e14863/
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Midaglia L] Servei de Neuroimmonologia clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain. [Mulero P] Servei de Neuroimmonologia clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. [Montalban X] Neuroimmonologia clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain. Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Hospital Universitari Vall d’Hebron, Barcelona, Spain. Departament de Neurologia, Universitat de Toronto, Toronto, Canadà. [Graves J] Department of Neurology, University of California, San Diego, USA. [Hauser SL] Department of Neurology, University of California, San Francisco,USA. [Julian L] Genentech Inc, South San Francisco, USA
dc.identifier.pmid31471961
dc.identifier.wos000483306800001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record